about
First epidemiological data for venotonics in pregnancy from the EFEMERIS database.Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption.The importance of pharmacoepidemiology in pregnancy-implications for safety.Pharmacovigilance, risks and adverse effects of self-medication.Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: A population-based cohort study.Prescription of asthma medications before and during pregnancy in France: An observational drug study using the EFEMERIS database.Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database.Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?Drug counselling in pregnancy: an opinion survey of French community pharmacists.Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database.Antihypertensive drug prescription pattern before and during pregnancy in France.Anticholinergics, antimuscarinics or atropinics? About the words in pharmacologyDrug prescribing before and during pregnancy in south west France: a retrolective study.In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission.[Drug prescription and pharmacovigilance in spa therapy: a comparative study at a 20-year interval (1987 versus 2007)].Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France: a short communication.Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.[Finger agenesis after in utero exposure to ketoconazole: a case report].Healthcare databases in Europe for studying medicine use and safety during pregnancy.Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database.What do pregnant women know about non-steroidal anti-inflammatory drugs?Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern.[Writing and dispensing of NSAID prescriptions in late pregnancy: impact of health authorities' advice].Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics.Analysis of chats on French internet forums about drugs and pregnancy.Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study.[Women's knowledge of folic acid].[Adverse drug reactions in pregnant women].La pharmacovigilance et l'évaluation du risque médicamenteux: intérêt, fonctionnement et méthodes
P50
Q30968872-F20E72EB-0AAD-4E0D-8F28-A83951FCC371Q33647254-901763A5-12F7-4C02-8B1E-A6AF3B4F68B2Q36655440-3D190066-443B-4AC8-A9EE-6D828F1CB4D9Q37418096-0C5A7821-7BA7-440F-8ED4-83D41A9CE705Q38640575-F2D66321-3649-461A-8887-3B08F933BB01Q38808896-74C15ECD-26C9-4B75-AA1B-DBFA8C3555CCQ39327393-4DCFED42-CB2B-4A6D-9AE3-434406FE9605Q39362597-12AB7EBC-4DD5-42D3-AF46-8071C7588B3FQ39846163-1DE116A0-A50D-45EF-B717-ABD8501260E7Q39849339-C159C41B-85C3-4ED0-B967-7B0023F2261AQ39886560-0911DB1D-F49B-4ADC-8634-6ED7916606D2Q40525259-04FC2281-5770-4FF8-BA80-0ED81AF1FFB4Q40691051-CAC42D1C-A263-4253-86D5-376D7B96F2C9Q40806144-3A7F57BA-A2B8-4000-BAD8-66397E84CC43Q42836735-EEF94EEC-2633-468F-8070-3EDF3E4DC905Q43523046-897B0CE5-714E-46EB-9495-64A420F662F2Q44026795-D3F51936-DC72-436E-AFA9-F8A2C512842AQ44175313-E3D9FF78-0963-4D57-9F60-98655050885AQ44238525-566FDB06-B8CF-4BCF-A054-AE69D352A116Q44350533-E8227EFE-C503-4139-920D-1B25E6EFB106Q44564814-1C985DE4-6856-49E3-9CAB-2F40607E4F67Q44652458-B0B407BF-B5A1-4C3F-9965-BCAD544FF62CQ45297173-726742A8-744F-42F7-914D-78C046F05C89Q45919176-4AB2CD18-DD56-40CF-9ABE-D223201BF199Q46666713-BECA473B-B3F8-4163-BAEA-1D36A0769CA2Q46786995-7E8CA98C-B52E-4B33-B417-9F0CB44772F1Q47186746-B12FF210-B61F-4AEF-AF98-5D096B1F1932Q47940100-5B63C1B0-94AF-4FA3-95C7-F4B4D281B14AQ51695799-F7A4641D-B824-4BE2-91CE-84BEEF72D670Q52582925-9CF03A4D-20B1-4FEC-83EF-7D8770A2ECBEQ52808032-4F78B6D2-6BA4-4F9B-8F8D-72245C4ACCA3Q54659268-A4D935A2-55AB-4CEC-A8A0-79EB9030155AQ60619195-4D608E45-88D8-430A-92FB-3112CDCD40A4
P50
name
Christine Damase-Michel
@ast
Christine Damase-Michel
@en
Christine Damase-Michel
@nl
type
label
Christine Damase-Michel
@ast
Christine Damase-Michel
@en
Christine Damase-Michel
@nl
prefLabel
Christine Damase-Michel
@ast
Christine Damase-Michel
@en
Christine Damase-Michel
@nl
P214
P21
P214
P31
P735
P7859
viaf-260877484